Using NHANES data, researchers estimated the prevalence of chronic axial pain, inflammatory back pain, axial spondyloarthritis, and peripheral arthritis in inflammatory bowel disease.
The ongoing phase 3 BE MOBILE 2 study compared the efficacy and safety of bimekizumab to placebo in 332 adults with active ankylosing spondylitis.
The approval was based on data from a phase 3 study which evaluated tofacitinib in adults with active AS who had an inadequate response to at least 2 NSAIDs.
The approval was based on data from the phase 2/3 SELECT-AXIS 1 and the phase 3 SELECT-AXIS 2 trials.
The interchangeable biosimilar product may be substituted for the reference product by a pharmacist.
Researchers assessed the association between traditional cardiovascular risk factors and disease activity in patients with axial spondyloarthritis.
